Trial Profile
Addition of Pembrolizumab Upon Progression on Enzalutamide in Men With mCRPC
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Enzalutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 27 Jun 2023 Planned End Date changed from 1 Dec 2022 to 30 Jun 2024.
- 27 Jun 2023 Planned primary completion date changed from 1 Dec 2022 to 30 Jun 2024.
- 10 Feb 2022 Planned End Date changed from 1 Jun 2022 to 1 Dec 2022.